A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
Public ClinicalTrials.gov record NCT07439653. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
Study identification
- NCT ID
- NCT07439653
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 155 participants
Conditions and interventions
Interventions
- TORL-5-700 Drug
- TORL-5-700 at MTD/RP2D Drug
- TORL-5-700 at MTD/RP2D in combination with another agent Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2026 (Actual)
- Primary completion
- Mar 31, 2029 (Estimated)
- Completion
- Sep 30, 2029 (Estimated)
- Last update posted
- Sep 28, 2026
2026 – 2029
United States locations
- U.S. sites
- 9
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Providence Medical Foundation | Fullerton | California | 92835 | Recruiting |
| Cancer and Blood Specialty Clinic, Los Alamitos | Los Alamitos | California | 90720 | Recruiting |
| UCLA | Santa Monica | California | 90404 | Recruiting |
| Stanford University | Stanford | California | 94305 | Recruiting |
| University of California Miami, Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | Recruiting |
| University of Iowa Health Care | Iowa City | Iowa | 52242 | Recruiting |
| Cancer Center of Kansas, Wichita | Wichita | Kansas | 67214 | Recruiting |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | Recruiting |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07439653, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2026 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07439653 live on ClinicalTrials.gov.